Participants who have received palliative local th erapy will be documented as having had disease progression for the purpose of efficacy analyses. 7.7 Treatment After the End of the Study At the end of the study, BMS will not continue to provide BMS s upplied study treatment to participants/investigators unless BMS chooses to extend the study. The investigator should ensure that the participant receives appropriate standard of care to treat the condition under study. 8 DISCONTINUATION CRITERIA 8.1 Discontinuation from Study Treatment Participants must discontinue IP (and non-IP at the discretion of the investigator) for any of the following reasons: •Participant’s request to stop study treatment •Any clinical AE, laboratory a bnormality, or intercurrent illness that, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the participant •Termination of the study by BMS •Loss of ability to freely provide consent th rough imprisonment or involuntary incarceration for treatment of either a psychiatric or physical (eg, infectious disease) illness. (Note: Under specific circumstances and only in countries where local regulations permit, a participant who has been imprisoned may be permitted to continue as a participant. Strict conditions apply and BMS approval is required.) •Pregnancy •Documented and confirmed disease progression as defined by RECIST v1.1 (see Appendix 5) or PCWG3 (prostate cancer only) (see Appendix 11) unless participant meets criteria for treatment beyond progression ( Section 8.1.2 ) •Clinical deteriorati on while receiving active study treatment that, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the participant •Discretion of the investigator •Inability to comply with the protocol requirements •Individual participants with confirmed CR w ill be given the option to discontinue study treatment on a case-by-case basis after specific consultation and agreement between the investigator and BMS Medical Monitor/Study Director (or designee) in settings where benefit/risk justifies discontinuation of study treatment •Any Grade 4 drug-related AE or laboratory abnorm ality (including, but not limited to, creatinine, AST, ALT, or total bilirubin), except for the following events that do not require discontinuation: Revised Protocol No.: 04 Date: 31-May-2019 93 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS −Grade 4 neutropenia ≤7 days −Grade 4 lymphopenia, leukopenia, or asymptomatic amylase or lipase abnormalities −Isolated Grade 4 electrolyte imbalances/a bnormalities that are not associated with clinical sequelae and are corrected with supplemen tation/appropriate management within 72 hours of their onset −Grade 4 drug-related endocrinopathy AEs, such as hyperthyroidism or hypothyroidism, or glucose intolerance, which resolve or are adequately controlled with physiologic hormone replacement (corticosteroids, thyroid hormones) or glucose-controlling agents, respectively, may not require discontinuation after discussion with and approval from the BMS Medical Monitor/Study Director (or designee). •Any event that leads to delay in dosing lasting > 6 weeks from the previous dose requires discontinuation, with the following exceptions: −Dosing delays to allow for prolonged steroid tapers to manage study tr eatment-related AEs are allowed −Dosing delays lasting > 6 weeks from th e previous dose that occur for nondrug-r elated reasons may be allowed if approved by the BMS Medical Monitor/Study Director (or designee). •The assessment for discontinuati on of nivolumab or ipilimumab s hould be made separately from the assessment made for discontinuation of BMS-986226. Although there is overlap among the discontinuation criteria, if discontinuation criteria are met for BMS-986226 but not for nivolumab or ipilimumab, treatment with nivo lumab or ipilimumab may continue even if BMS-986226 is discontinued. •If a participant in any of the nivolumab or ipilimumab/BMS-986226 combination arms meets criteria for discontinuation and the investigator is unable to determine whether the event is related to both or 1 of the study treatments, the participant should discontinue both nivolumab or ipilimumab and BMS-986226 and should be taken off the treatment phase of the study. Refer to the Schedule of Activities ( Section 2 ) for the data to be collected at the time of treatment discontinuation and follow-up and for any further evaluations that can be completed.